This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The
Even if the NIH is drastically cut, we don't see a doomsday scenario for these companies, and some of the industry's stronger players are now trading at attractive valuations.
Morningstar's Heather Brilliant isn't optimistic about the market's--or Europe's --prospects for the rest of the year, though several stocks currently present buying opportunities.